Cingulate Inc
CING3.540USD
+0.020+0.57%
終値 09/19, 16:00（ET）15分遅れの株価
17.31M時価総額
損失額直近12ヶ月PER
詳細情報 Cingulate Inc 企業名
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
企業情報
企業コードCING
会社名Cingulate Inc
上場日Oct 07, 2021
最高経営責任者「CEO」Ms. Jennifer L. Callahan
従業員数13
証券種類Ordinary Share
決算期末Oct 07
本社所在地1901 W. 47Th Place
都市KANSAS CITY
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号66205
電話番号19139422300
ウェブサイトhttps://www.cingulate.com/
企業コードCING
上場日Oct 07, 2021
最高経営責任者「CEO」Ms. Jennifer L. Callahan
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
他の
94.31%
株主統計
株主統計
比率
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
他の
94.31%
種類
株主統計
比率
Investment Advisor
4.09%
Corporation
1.81%
Investment Advisor/Hedge Fund
0.57%
Research Firm
0.38%
Venture Capital
0.20%
Hedge Fund
0.03%
他の
92.93%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
44
305.06K
5.93%
+1.66K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
2023Q1
34
15.09K
32.03%
-921.00
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Commonwealth Financial Network
55.52K
1.31%
+12.50K
+29.05%
Mar 31, 2025
Werth Family Investment Associates LLC
97.99K
2.31%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
10.76K
0.25%
+8.76K
+438.54%
Mar 31, 2025
Geode Capital Management, L.L.C.
30.40K
0.72%
+3.08K
+11.26%
Mar 31, 2025
UBS Financial Services, Inc.
22.12K
0.52%
+9.92K
+81.34%
Mar 31, 2025
Quantum Private Wealth, LLC
10.00K
0.24%
+10.00K
--
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
日付
種類
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
